Although a recent clinical trial reported that an inhibitor targeting mutant IDH1 and IDH2 induced durable therapeutic efficacy in lowgrade glioma [24], the impact of directly targeting mutant IDH for high-grade glioma is under clinical investigation. Here, IDH1 is linked to central nervous system cancer.